On June 24, 2013, a 60-second television advertisement will debut promoting BOTOX® (onabotulinumtoxinA) as a prophylactic treatment for adult patients living with Chronic Migraine (defined as experiencing 15 or more headache days per month, each lasting 4 hours a day or more).1
Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.
We’d like to emphasize that BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA) are FDA approved for different uses, different injection sites, and different dosages. It is important to understand that BOTOX® for appropriate Chronic Migraine patients is for those patients who are diagnosed as having ≥ 15 headache days per month with headache lasting 4 hours a day or longer, and that only BOTOX® can be used and reimbursed by insurance providers for this indication.
Allergan looks forward to our continued support of your practice with BOTOX® Cosmetic and the entire Allergan Medical portfolio of products.
Sales & Marketing—Facial Aesthetics
Click here for the announcement.